Pathological response is an independent factor of overall survival and diseasefree survival after neoadjuvant durvalumab in resectable nonsmall cell lung cancer (NSCLC) in the IFCT1601 IONESCO phase 2 trial.
Durvalumab
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Pathological response is an independent factor of overall survival and diseasefree survival after neoadjuvant durvalumab in resectable nonsmall cell lung cancer (NSCLC) in the IFCT1601 IONESCO phase 2 trial. ### Output: Durvalumab